Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Core Insights - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses [1][3] - The company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [3][4] - The MIRACLE Trial (MB-108) is a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for the treatment of relapsed or refractory AML, with a successful Phase 1B/2 study providing confidence in the development pathway [4] Company Overview - Moleculin Biotech, Inc. is advancing a pipeline of therapeutic candidates, including WP1066, an immune/transcription modulator targeting brain tumors and pancreatic cancers, and a portfolio of antimetabolites like WP1122 for treating pathogenic viruses and certain cancers [5] Recent Developments - Walter Klemp, the company's Founder, President, CEO, and Chairman, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference, sharing insights into his dedication to the company and its programs [2]